NASDAQ
BioCryst Pharmaceuticals, Inc. (BCRX) has a free cash flow growth of -122.72% as of Friday, May 29, 2026. This represents a 204.95% decrease compared to its 12-month average of 116.93%. Free cash flow growth tracks the year-over-year percentage change in cash generated after capital expenditures.
No price data available for this timeframe.